Good evening :)
Place Order
Add to Watchlist

Alkem Laboratories Ltd

ALKEM

Alkem Laboratories Ltd

ALKEM
Health CarePharmaceuticals
MidcapWith a market cap of ₹67,241 cr, stock is ranked 141
Low RiskStock is 1.94x as volatile as Nifty
5,503.402.14% (-120.45)
5,503.402.14% (-120.45)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
MidcapWith a market cap of ₹67,241 cr, stock is ranked 141
Low RiskStock is 1.94x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
MidcapWith a market cap of ₹67,241 cr, stock is ranked 141
Low RiskStock is 1.94x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
32.736.280.71%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.796.460.51%

Forecast & Ratings

Detailed Forecast 
47%
Analysts have suggested that investors can buy this stock

from 19 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Alkem Laboratories Limited is engaged in the development, manufacture and sale of pharmaceutical and neutraceutical products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.76%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 3.39% to 3.44%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 18.75%, vs industry avg of 15.28%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue5,164.555,799.546,516.597,444.898,448.589,098.2210,796.8411,815.3412,978.4213,096.99
Raw Materialssubtract2,068.322,511.132,477.742,941.333,574.893,832.304,715.774,444.474,923.4610,388.23
Power & Fuel Costsubtract66.3386.34112.64121.48130.14129.95162.96163.94162.58
Employee Costsubtract861.081,003.851,191.641,362.461,505.491,621.031,962.712,131.352,201.01
Selling & Administrative Expensessubtract879.561,014.861,175.611,288.441,412.401,224.581,722.202,163.712,163.46
Operating & Other expensessubtract196.3072.40434.62528.71248.05114.7632.591,189.321,093.07
Depreciation/Amortizationsubtract93.31101.17143.03193.18252.76274.58303.96310.42299.30307.37
Interest & Other Itemssubtract71.2445.1655.3354.6365.0658.9252.37107.36112.41111.75
Taxes & Other Itemssubtract186.8272.60295.04194.15132.72257.08198.66320.60227.36235.44
EPS62.0274.6152.7763.6194.26132.57137.6382.31150.19171.81
DPS12.7015.0013.0016.0025.0030.0034.0050.0040.0045.00
Payout ratio0.200.200.250.250.270.230.250.610.270.26

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2021

Annual report

PDF

Investor Presentation

May 25PDF
FY 2022

Annual report

PDF

Investor Presentation

May 13PDF
Feb 4PDF
Nov 12PDF
Aug 6PDF
FY 2023

Annual Report Unavailable

Investor Presentation

May 19PDF
Feb 10PDF
Nov 11PDF
Aug 5PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 10PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Alkem Laboratories Ltd37.446.280.71%
Sun Pharmaceutical Industries Ltd44.966.420.75%
Cipla Ltd30.434.680.84%
Dr Reddy's Laboratories Ltd19.233.800.62%

Price Comparison

Compare ALKEM with any stock or ETF
Compare ALKEM with any stock or ETF
ALKEM
Loading...

Shareholdings

Promoter Holdings Trend

Decreased Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has decreased by 1.08%

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding55.66%14.94%4.27%9.02%16.10%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep5.64%6.03%8.49%9.11%8.69%9.02%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Alkem Laboratories Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Large & Mid Cap Fund - Growth - Direct Plan

Growth
0.8780%3.38%-0.06%7/119 (+1)
ICICI Prudential Multi-Asset Fund - Growth - Direct Plan

Growth
0.8481%1.13%-0.00%59/213 (+1)
Axis Midcap Fund - Growth - Direct Plan

Growth
0.7519%1.68%0.35%17/114 (+5)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No Trend In Dividends

Dividends are the portion of earnings that a company distributes to all its shareholders every year

ALKEM has shown inconsistent dividend trend over the last 5 years

Dividend Yield

Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.70%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹7.01 every year

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateAug 9, 2024

Final
Final | Div/Share: ₹5.00

Dividend/Share

₹5.00

Ex DateEx Date

Aug 9, 2024

Cash Dividend

Ex DateEx DateFeb 16, 2024

Interim
Interim | Div/Share: ₹35.00

Dividend/Share

₹35.00

Ex DateEx Date

Feb 16, 2024

Cash Dividend

Ex DateEx DateAug 10, 2023

Final
Final | Div/Share: ₹10.00

Dividend/Share

₹10.00

Ex DateEx Date

Aug 10, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Special
Special | Div/Share: ₹25.00

Dividend/Share

₹25.00

Ex DateEx Date

Feb 17, 2023

Cash Dividend

Ex DateEx DateFeb 17, 2023

Interim
Interim | Div/Share: ₹15.00

Dividend/Share

₹15.00

Ex DateEx Date

Feb 17, 2023

News & Opinions
Corporate
Alkem Laboratories to conduct board meeting

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live

5 days agoCapital Market - Live
Corporate
Alkem Laboratories inks licensing agreement with Sonnet

Alkem Laboratories has entered into a licensing agreement with US-based Sonnet BioTherapeutics Holdings, Inc (Sonnet) to develop, manufacture and commercialise the drug candidate 'SON-080' for the treatment of diabetic peripheral neuropathy in India. 'SON-080' is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alkem Labs signs licensing agreement with Sonnet BioTherapeutics

SON-080 is Sonnet's proprietary version of 'atexakin alfa'. It has shown encouraging data in phase 1b clinical trial. The drug candidate was demonstrated to be well-tolerated and the pain and quality of life survey results suggested a potential for rapid improvement of peripheral neuropathy symptoms and post-dosing durability, compared to placebo controls. Under the licensing agreement, Alkem will carry out the clinical development of 'SON-080' in India with support from Sonnet and enable global and India regulatory filings. Alkem has exclusive rights to develop, manufacture and commercialise the drug in India. According to company, 'SON-080' has undergone many years of development and the previous clinical trials have generated safety data from over 200 patients. 'SON-080' has demonstrated compelling preclinical efficacy data in both diabetic peripheral neuropathy and chemotherapy induced neuropathy, including the ability to prevent the development of neuropathy and reverse established neuropathy when assessed by nerve conduction, histological integrity and sensorimotor function measurements. Dr. Akhilesh Sharma, president & chief medical officer of Alkem said, 'We are pleased to partner with Sonnet for this programme. We believe 'SON-080' is a unique asset that has demonstrated promising disease modifying potential for diabetic peripheral neuropathy with translational studies showing nerve regeneration. There is a large prevalence of diabetic peripheral neuropathy in India, which we believe underscores the need for the drug development in this territory and potential value.' Pankaj Mohan, founder & chief executive officer of Sonnet, said, 'We are excited to partner with Alkem and look forward to advancing 'SON-080' into phase 2 clinical development. We believe that Alkem is the ideal partner with significant experience and expertise.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company reported 90.13% jump in consolidated net profit to Rs 545.16 crore on 2.16% rise in revenue from operations to Rs 3,031.82 crore in Q1 FY25 over Q1 FY24. Shares of Alkem Laboratories slipped 3.17% to currently trade at Rs 6,090.55 on the BSE.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd rises for third consecutive session

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 6295, up 1.4% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Alkem Laboratories Ltd has risen around 18.26% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 2.52 lakh shares today, compared to the daily average of 3.65 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6309.05, up 1.17% on the day. Alkem Laboratories Ltd is up 72.23% in last one year as compared to a 28.41% spurt in NIFTY and a 52.01% spurt in the Nifty Pharma index.The PE of the stock is 35.16 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd spurts 2.93%, up for fifth straight session

Alkem Laboratories Ltd is up for a fifth straight session today. The stock is quoting at Rs 6174.95, up 2.93% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.35% on the day, quoting at 25240.45. The Sensex is at 82401.53, up 0.32%. Alkem Laboratories Ltd has gained around 16.3% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has gained around 6.75% in last one month and is currently quoting at 22878.05, up 1.61% on the day. The volume in the stock stood at 2.31 lakh shares today, compared to the daily average of 3.57 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 6198, up 2.63% on the day. Alkem Laboratories Ltd is up 69.51% in last one year as compared to a 31.09% jump in NIFTY and a 54% jump in the Nifty Pharma index.The PE of the stock is 33.97 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd soars 1.08%, Gains for third straight session

Alkem Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 5954.65, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.31% on the day, quoting at 25094.85. The Sensex is at 81939.19, up 0.28%. Alkem Laboratories Ltd has added around 14.47% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has added around 5.53% in last one month and is currently quoting at 22729, up 0.64% on the day. The volume in the stock stood at 1.9 lakh shares today, compared to the daily average of 3.42 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 5956.65, up 1.11% on the day. Alkem Laboratories Ltd is up 60.84% in last one year as compared to a 29.74% gain in NIFTY and a 51.27% gain in the Nifty Pharma index.The PE of the stock is 33.35 based on TTM earnings ending June 24.Powered by Capital Market - Live

2 months agoCapital Market - Live
Spotlight
Alkem Labs PAT soars 90% YoY to Rs 545 crore in Q1

Revenue from operations stood at Rs 3,031.82 crore in June 2024 quarter, registering a growth of 2.16% on YoY basis. During the quarter, India sales were at Rs 2,022.3 crore (up 6.4% YoY) while International sales stood at Rs 967.7 crore (down 4.6% YoY). US sales for Q1 FY25 stood at Rs 641.6 crore, registering a decline of 7.7% YoY. Other International Markets sales rose 2.2% to Rs 326.1 crore during the quarter. Profit before tax stood at Rs 619.36 crore in June 2024 quarter, up 75.53% from Rs 352.85 crore posted in similar quarter a year ago. During the quarter, EBITDA stood at Rs 608.6 crore, registering a growth of 56.4% YoY. EBITDA margin improved to 20.1% in Q1 FY25 as against 13.1% posted in the same period last year. R&D expenses for the quarter increased 4.58% to Rs 125.7 crore in Q1 FY25, 4.1% of total revenue from operations. As per IQVIA data, for first quarter of FY24, the company registered a growth of 8.4% YoY versus the Indian Pharmaceutical Market (IPM) which grew by 8.7% The company outperformed the IPM in antidiabetic, neuro/CNS, gastro-intestinal, dermatology, and VMN therapies, and our ranking has improved in neuro/CNS and respiratory therapies. During the quarter, the company launched 1 product in the US and received approval for 3 abbreviated new drug applications (ANDAs) from the USFDA, including one tentative approval. As of 30 June 2024, the firm had filed 176 ANDAs and 2 NDAs with the USFDA. Of these, it had received approvals for 148 ANDAs (including 14 tentative approvals) and 2 NDA. Dr Vikas Gupta, CEO, Alkem said, 'We are happy that our efforts to improve profitability have started paying off, and we have seen a marked increase in margins during the quarter. We are committed to maximising our EBITDA margin by carefully managing our product mix, controlling costs, and taking advantage of the favourable raw material pricing environment. The domestic business is our stronghold, and we expect to build on it by furthering the growth of our large brands and bridging portfolio gaps. Simultaneously, we are also focusing on growing our business in emerging markets. During the quarter, an important development was the successful resolution of US FDA's Form 483 at the Baddi facility. At Alkem, we remain steadfast to prioritising quality and regulatory compliance.' Alkem Laboratories is engaged in pharmaceutical business with global operations. The company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. Shares of Alkem Laboratories declined 0.36% to currently trade at Rs 5,667 on the BSE.Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Alkem Laboratories consolidated net profit rises 90.13% in the June 2024 quarter

Net profit of Alkem Laboratories rose 90.13% to Rs 545.16 crore in the quarter ended June 2024 as against Rs 286.73 crore during the previous quarter ended June 2023. Sales rose 2.16% to Rs 3031.82 crore in the quarter ended June 2024 as against Rs 2967.72 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales3031.822967.72 2 OPM %20.0813.11 - PBDT699.84425.26 65 PBT619.36352.85 76 NP545.16286.73 90 Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd soars 3.33%, rises for fifth straight session

Alkem Laboratories Ltd rose for a fifth straight session today. The stock is quoting at Rs 5695.7, up 3.33% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.03% on the day, quoting at 24305.1. The Sensex is at 79482.87, up 0.02%. Alkem Laboratories Ltd has added around 6.98% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has added around 7.61% in last one month and is currently quoting at 22036.95, up 0.82% on the day. The volume in the stock stood at 4.32 lakh shares today, compared to the daily average of 2.2 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 5732.5, up 3.51% on the day. Alkem Laboratories Ltd is up 34.74% in last one year as compared to a 23.8% jump in NIFTY and a 41.54% jump in the Nifty Pharma index.The PE of the stock is 36.6 based on TTM earnings ending March 24.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Alkem Laboratories Ltd rises for third consecutive session

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5407.35, up 1.75% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.49% on the day, quoting at 24172.6. The Sensex is at 79177.29, up 0.53%. Alkem Laboratories Ltd has risen around 3.55% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has risen around 7.21% in last one month and is currently quoting at 21583.05, up 0.96% on the day. The volume in the stock stood at 1.58 lakh shares today, compared to the daily average of 2.09 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 5442.9, up 2.18% on the day. Alkem Laboratories Ltd is up 30.87% in last one year as compared to a 23.35% spurt in NIFTY and a 40.77% spurt in the Nifty Pharma index.The PE of the stock is 35.24 based on TTM earnings ending March 24.Powered by Capital Market - Live

3 months agoCapital Market - Live